Drugs / AGEN2373
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07193862 | Dec 2025 → Apr 2028 expected | colorectal cancer | Northwell Health | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04121676 | Sep 2019 → Feb 2024 | cancer of unknown primary site | Agenus Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06782932 | May 2025 → Dec 2028 expected | pancreatic adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGEN2373 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06782932 ↗ |
| Route | Intravenous | “3+3 Dose escalation of AGEN2373 administered by IV.” NCT04121676 ↗ |